Keywords: smithkline, beecham, sales, 3rd, quarter, meet, estimates

SmithKline Beecham sales for 3rd quarter meet estimates, Avandia setback

Article | 21 October 1999

SmithKline Beecham says that pretax profits for the third quarter of1999 rose 11% (excluding currency) to L467 million ($779 million), excluding a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Avandia

rosiglitazone

Amoxicillin Clavulanate

paroxetine

Paxil

Go to drug listing